5.49
-0.175(-3.09%)
Currency In USD
| Previous Close | 5.66 |
| Open | 5.66 |
| Day High | 5.68 |
| Day Low | 5.47 |
| 52-Week High | 6.02 |
| 52-Week Low | 1.05 |
| Volume | 1.01M |
| Average Volume | 6.14M |
| Market Cap | 1.44B |
| PE | -16.62 |
| EPS | -0.33 |
| Moving Average 50 Days | 4.86 |
| Moving Average 200 Days | 3.2 |
| Change | -0.18 |
If you invested $1000 in Taysha Gene Therapies, Inc. (TSHA) since IPO date, it would be worth $227.97 as of December 31, 2025 at a share price of $5.485. Whereas If you bought $1000 worth of Taysha Gene Therapies, Inc. (TSHA) shares 2 years ago, it would be worth $2,493.18 as of December 31, 2025 at a share price of $5.485.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4
GlobeNewswire Inc.
Oct 28, 2025 12:00 PM GMT
DALLAS, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic disease
Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome
GlobeNewswire Inc.
Oct 16, 2025 8:01 PM GMT
The 2022 Option Agreement between Astellas and Taysha has expired Regaining full rights to TSHA-102 Rett syndrome program enables Taysha to focus on driving its long-term value with full strategic flexibility and optionality TSHA-102 has demonstrated
Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting
GlobeNewswire Inc.
Oct 09, 2025 12:00 PM GMT
Previously disclosed 100% response rate across all 10 patients in Part A for pivotal trial primary endpoint of gain/regain of ≥ one natural history defined developmental milestone assessed via video-evidenced review by independent central raters New